Astria Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update
-- STAR-0215 Granted Fast Track Designation by the U.S. FDA ---- New Results from Healthy Subjects Informing STAR-0215 Administration Plan Expected in Q4 2023 ---- ALPHA-STAR on Track with Initial Proof-of-Concept Results in Patients Anticipated Mid-2024 --BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:A...
Marcus Maurer Jillc Milne Instagram Astriatx Administration Plan Drug Administration Exchange Commission
Source: pharmiweb.com